Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Vöslau – page 15

865 clinical trials in Bad Vöslau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Vöslau at a glance
865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

865 trials in Bad Vöslau

Open in trial search

Study of plozasiran to prevent acute pancreatitis in adults with severe hypertriglyceridemia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Amphotericin B
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International S.A.

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen - Cilag International

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Etranacogene Dezaparvovec
  • Sponsor:CSL Behring LLC

Study on the Safety and Effectiveness of Telisotuzumab Adizutecan and Drug Combination for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Vöslau

What the registry says about research in the country

01 Neuropathic Pain Studies

Investigating new treatment approaches for patients with diabetic polyneuropathy, focusing on innovative pain management solutions that could improve quality of life for those affected by chronic neuropathic conditions.

  • Diabetic Neuropathy Management
  • Chronic Pain Treatment
  • Add-on Therapy Evaluation

Research aims to enhance current treatment protocols for diabetes-related nerve pain.

02 Trauma-Related Neuropathy

Evaluating therapeutic options for patients experiencing post-operative and traumatic peripheral neuropathy, with a focus on developing effective pain management strategies for those affected by surgery or injury-related nerve damage.

  • Post-surgical Pain Management
  • Trauma-induced Neuropathy
  • Peripheral Nerve Pain

Studies explore innovative approaches to managing chronic pain resulting from surgical procedures and trauma.

03 Central Neuropathy Research

Examining treatment efficacy for central neuropathy of various origins, investigating novel therapeutic approaches for managing chronic pain associated with central nervous system conditions.

  • Central Nervous System Pain
  • Neurological Pain Management
  • Pain Relief Strategies

This research explores comprehensive treatment options for central nervous system-related pain conditions.

04 Chronic Back Pain Treatment

Investigating innovative therapies for patients suffering from chronic back pain, focusing on developing effective add-on treatments to enhance current pain management approaches.

  • Back Pain Management
  • Long-term Pain Relief
  • Therapeutic Advancement

Studies aim to improve treatment outcomes for individuals with persistent back pain conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.